CL2007003161A1 - Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como - Google Patents

Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como

Info

Publication number: CL2007003161A1
Authority: CL; Chile
Prior art keywords: antibodies; complement; vector; understand; code
Prior art date: 2006-11-02

Application number

CL200703161A

Other languages

English (en)

Inventor

Herren Singh Sanjaya Fung S Wu

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-02

Filing date

2007-10-31

Publication date

2008-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39345075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003161(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-31 Application filed by Genentech Inc filed Critical Genentech Inc

2008-05-30 Publication of CL2007003161A1 publication Critical patent/CL2007003161A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21046—Complement factor D (3.4.21.46)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Endocrinology (AREA)

CL200703161A 2006-11-02 2007-10-31 Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como CL2007003161A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US85650506P	2006-11-02	2006-11-02

Publications (1)

Publication Number	Publication Date
CL2007003161A1 true CL2007003161A1 (es)	2008-05-30

Family

ID=39345075

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703161A CL2007003161A1 (es)	2006-11-02	2007-10-31	Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como

Country Status (35)

Country	Link
US (10)	US8067002B2 (es)
EP (4)	EP2907827B1 (es)
JP (6)	JP2010508819A (es)
KR (6)	KR20160092061A (es)
CN (7)	CN106084054A (es)
AR (2)	AR063760A1 (es)
AU (1)	AU2007313685C1 (es)
BR (1)	BRPI0716299A2 (es)
CA (2)	CA2939806A1 (es)
CL (1)	CL2007003161A1 (es)
CO (1)	CO6190543A2 (es)
CR (1)	CR10827A (es)
DK (2)	DK2097455T3 (es)
EC (1)	ECSP099379A (es)
ES (2)	ES2700609T3 (es)
HK (2)	HK1215712A1 (es)
HR (1)	HRP20181969T1 (es)
IL (3)	IL198512A (es)
LT (1)	LT2907827T (es)
MA (1)	MA30962B1 (es)
MX (1)	MX2009004665A (es)
MY (2)	MY157948A (es)
NO (1)	NO20092121L (es)
NZ (3)	NZ576812A (es)
PE (2)	PE20121034A1 (es)
PH (1)	PH12015501763A1 (es)
PL (2)	PL2907827T3 (es)
PT (2)	PT2097455E (es)
RS (1)	RS58233B1 (es)
RU (3)	RU2474589C9 (es)
SI (2)	SI2907827T1 (es)
TW (5)	TW201534620A (es)
UA (2)	UA116614C2 (es)
WO (1)	WO2008055206A2 (es)
ZA (2)	ZA200903088B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2407715C (en) *	2000-04-29	2009-03-24	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
KR20180002911A (ko)	2005-11-04	2018-01-08	제넨테크, 인크.	안질환 치료를 위한 보체 경로 억제제의 용도
EP2044111B1 (en)	2006-06-21	2014-08-13	MUSC Foundation For Research Development	Targeting complement factor h for treatment of diseases
CL2007003161A1 (es)	2006-11-02	2008-05-30	Genentech Inc	Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
AR066660A1 (es) *	2007-05-23	2009-09-02	Genentech Inc	Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) *	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
JP5646457B2 (ja) *	2008-04-29	2014-12-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリン及びその使用
US20100260668A1 (en) *	2008-04-29	2010-10-14	Abbott Laboratories	Dual Variable Domain Immunoglobulins and Uses Thereof
JP2011523853A (ja) *	2008-06-03	2011-08-25	アボット・ラボラトリーズ	二重可変ドメイン免疫グロブリン及びその使用
RU2010153578A (ru) *	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойными вариабельными доменами и их применение
US8822645B2 (en) *	2008-07-08	2014-09-02	Abbvie Inc.	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
GB2476606B (en)	2008-09-08	2012-08-08	Virginia Tech Intell Prop	Systems, devices, and methods for managing energy usage
TW201031421A (en) *	2009-01-29	2010-09-01	Abbott Lab	IL-1 binding proteins
WO2011003098A1 (en)	2009-07-02	2011-01-06	Musc Foundation For Research Development	Methods of stimulating liver regeneration
UY32808A (es) *	2009-07-29	2011-02-28	Abbott Lab	Inmunoglobulinas como dominio variable dual y usos de las mismas
KR20110020642A (ko)	2009-08-24	2011-03-03	삼성전자주식회사	사용자 접근을 인식하여 반응하는 ｇｕｉ제공 장치 및 방법
IN2012DN02737A (es) *	2009-09-01	2015-09-11	Abbott Lab
PE20121531A1 (es) *	2009-10-15	2012-12-22	Abbott Lab	Inmunoglobulinas con dominio variable dual
AU2010306681A1 (en)	2009-10-15	2012-04-19	Abbvie Inc.	IL-1 binding proteins
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20110165648A1 (en) *	2009-11-04	2011-07-07	Menno Van Lookeren Campagne	Co-crystal structure of factor D and anti-factor D antibody
US10239937B2 (en)	2009-11-05	2019-03-26	Alexion Pharmaceuticals, Inc.	Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
CN103038252A (zh)	2010-05-14	2013-04-10	科罗拉多大学董事会,法人团体	改良的补体受体2(cr2)靶向群
WO2011163412A1 (en)	2010-06-22	2011-12-29	The Regents Of The University Of Colorado, A Body Corporate	Antibodies to the c3d fragment of complement component 3
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
MX2013002270A (es)	2010-08-26	2013-05-14	Abbvie Inc	Inmonoglubinas de dominio variable doble y usos de las mismas.
AU2011361720B2 (en)	2010-12-21	2017-04-27	Abbvie Inc.	IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
BR112013017316A2 (pt)	2011-01-04	2019-09-24	Novartis Ag	compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
CN104159920A (zh)	2011-12-30	2014-11-19	艾伯维公司	针对il-13和/或il-17的双重可变结构域免疫球蛋白
US9388199B2 (en)	2012-06-28	2016-07-12	Novartis Ag	Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en)	2012-06-28	2014-01-03	Novartis Ag	Complement pathway modulators and uses thereof
JP6214647B2 (ja)	2012-06-28	2017-10-18	ノバルティスアーゲー	補体経路モジュレーターおよびその使用
EP2867225B1 (en)	2012-06-28	2017-08-09	Novartis AG	Pyrrolidine derivatives and their use as complement pathway modulators
US9464081B2 (en)	2012-06-28	2016-10-11	Novartis Ag	Pyrrolidine derivatives and their use as complement pathway modulators
TW201402608A (zh)	2012-07-12	2014-01-16	Abbvie Inc	Ｉｌ－１結合蛋白質
WO2014009833A2 (en)	2012-07-12	2014-01-16	Novartis Ag	Complement pathway modulators and uses thereof
US10413620B2 (en)	2012-08-17	2019-09-17	The Regents Of The University Of Colorado, A Body Corporate	Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja)	2012-08-17	2015-12-10	ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト	補体活性化を検出するための組成物および方法
AR092630A1 (es)	2012-09-19	2015-04-29	Genentech Inc	Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
TW202210507A (zh)	2012-11-01	2022-03-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
EP2970459A2 (en)	2013-03-15	2016-01-20	AbbVie Inc.	Dual specific binding proteins directed against il-1beta and il-17
JP6211701B2 (ja)	2013-08-07	2017-10-11	アレクシオンファーマシューティカルズ，インコーポレイテッド	非典型溶血性尿毒症症候群のバイオマーカータンパク質
BR112016002845A2 (pt) *	2013-08-12	2017-09-12	Genentech Inc	composições e métodos para tratar condições associadas ao complemento
EP3137503A1 (en)	2014-05-01	2017-03-08	Genentech, Inc.	Anti-factor d antibody variants and uses thereof
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
WO2016094881A2 (en)	2014-12-11	2016-06-16	Abbvie Inc.	Lrp-8 binding proteins
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
MA43113B1 (fr)	2015-10-30	2021-06-30	Hoffmann La Roche	Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
WO2017075252A1 (en) *	2015-10-30	2017-05-04	Genentech, Inc.	Anti-factor d antibody variant conjugates and uses thereof
HK1257426A1 (zh) *	2015-10-30	2019-10-18	豪夫迈‧罗氏有限公司	抗-因子d抗体制剂
JP2018534930A (ja) *	2015-10-30	2018-11-29	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体及びコンジュゲート
KR20180066242A (ko)	2015-10-30	2018-06-18	제넨테크, 인크.	인자 d 활성 및 인자 d 억제제의 효력을 측정하는 방법
JP7088454B2 (ja)	2015-12-30	2022-06-21	コディアックサイエンシーズインコーポレイテッド	抗体および抗体複合体
AU2017210042B2 (en)	2016-01-20	2021-01-21	396419 B.C. Ltd.	Compositions and methods for inhibiting Factor D
SG11201808821WA (en)	2016-04-18	2018-11-29	Celldex Therapeutics Inc	Agonistic antibodies that bind human cd40 and uses thereof
DK3476399T3 (da)	2016-06-23	2022-05-30	Jiangsu Hengrui Medicine Co	Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
US11007254B2 (en)	2016-10-17	2021-05-18	Musc Foundation For Research Development	Compositions and methods for treating central nervous system injury
WO2018136827A1 (en)	2017-01-20	2018-07-26	Vitrisa Therapeutics, Inc.	Stem-loop compositions and methods for inhibiting factor d
EA201991876A1 (ru)	2017-02-10	2020-03-13	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Антитела против фактора d и их применения
CN106905431B (zh) *	2017-04-10	2020-01-17	旭华（上海）生物研发中心有限公司	抗人补体d因子的单克隆抗体及其用途
WO2018191548A2 (en)	2017-04-14	2018-10-18	Kodiak Sciences Inc.	Complement factor d antagonist antibodies and conjugates thereof
FR3071483B1 (fr) *	2017-09-27	2020-11-27	Airbus Operations Sas	Systeme de surveillance de braquage d'une roulette de train d'atterrissage d'un aeronef
WO2019109238A1 (en) *	2017-12-05	2019-06-13	Lyvgen Biopharma Co., Ltd.	Anti-cd137 antibodies and uses thereof
GB201800620D0 (en)	2018-01-15	2018-02-28	Univ Manchester	C3b Binding Polypeptide
JP2021514656A (ja)	2018-03-02	2021-06-17	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
GB2583560A (en)	2018-12-11	2020-11-04	Admirx Inc	Fusion protein constructs for complement associated disease
US11166910B2 (en) *	2019-01-25	2021-11-09	Nordiccan A/S	Cannabinoid chewing gum with sugar alcohols
CN110240652B (zh) *	2019-06-05	2022-09-06	百奥泰生物制药股份有限公司	抗补体d因子抗体及其应用
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
EP4320149A1 (en) *	2021-04-09	2024-02-14	Takeda Pharmaceutical Company Limited	Antibodies targeting complement factor d and uses therof
CN119176879B (zh) *	2024-09-05	2025-08-05	西安市中心血站（陕西省血液中心）	一种中和抗d抗体的抗独特型抗体及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5256642A (en) *	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US6048728A (en)	1988-09-23	2000-04-11	Chiron Corporation	Cell culture medium for enhanced cell growth, culture longevity, and product expression
CA2018228C (en)	1989-06-05	1996-02-27	Nancy L. Parenteau	Cell culture systems and media
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
US5456909A (en) *	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
AU687755B2 (en)	1992-08-21	1998-03-05	Genentech Inc.	Method for treating an LFA-1-mediated disorder
US5861156A (en) *	1993-01-08	1999-01-19	Creative Biomolecules	Methods of delivering agents to target cells
US5856300A (en) *	1994-05-12	1999-01-05	T Cell Sciences, Inc.	Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) *	1993-09-24	1997-10-21	Cytomed, Inc.	Chimeric proteins which block complement activation
US5627264A (en) *	1994-03-03	1997-05-06	Alexion Pharmaceuticals, Inc.	Chimeric complement inhibitor proteins
AU2191795A (en) *	1994-03-23	1995-10-09	Alexion Pharmaceuticals, Inc.	Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) *	1994-04-25	1996-07-09	Genentech, Inc.	Cardiac hypertrophy factor and uses therefor
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5681736A (en) *	1994-10-05	1997-10-28	Antex Biologics, Inc.	Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
WO2002008284A2 (en)	2000-07-20	2002-01-31	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001036432A2 (en)	1999-11-19	2001-05-25	Human Genome Sciences, Inc.	18 human secreted proteins
US20050197285A1 (en) *	1997-03-07	2005-09-08	Rosen Craig A.	Human secreted proteins
US6472520B2 (en) *	1997-03-21	2002-10-29	The Trustees Of Columbia University In The City Of New York	Rat PEG-3 promoter
US6410708B1 (en) *	1997-11-21	2002-06-25	Genentech, Inc.	Nucleic acids encoding A-33 related antigen polypeptides
WO1999010009A1 (en) *	1997-08-26	1999-03-04	Gliatech Inc.	A process for inhibiting complement activation via the alternative pathway
DE69840105D1 (de)	1997-11-21	2008-11-20	Genentech Inc	Plättchen-spezifische antigene und deren pharmazeutische verwendung
US7282565B2 (en) *	1998-03-20	2007-10-16	Genentech, Inc.	PRO362 polypeptides
US7419663B2 (en) *	1998-03-20	2008-09-02	Genentech, Inc.	Treatment of complement-associated disorders
US8007798B2 (en) *	1997-11-21	2011-08-30	Genentech, Inc.	Treatment of complement-associated disorders
US7192589B2 (en) *	1998-09-16	2007-03-20	Genentech, Inc.	Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en)	1998-03-20	2012-01-03	Genentech, Inc.	Treatment of complement-associated disorders
EP1053245A4 (en)	1998-02-09	2002-04-17	Human Genome Sciences Inc	45 HUMAN SECRETED PROTEINS
ES2488819T3 (es) *	1998-02-20	2014-08-29	Genentech, Inc.	Inhibidores de la activación del complemento
US7112327B2 (en)	1998-02-20	2006-09-26	Tanox, Inc.	Inhibition of complement activation
US6956107B2 (en)	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
EP1490386B1 (en)	1998-03-10	2008-08-13	Genentech, Inc.	Novel polypeptide and nucleic acids encoding the same
CA2340794A1 (en)	1998-08-27	2000-03-09	Incyte Pharmaceuticals, Inc.	Protein transport-associated molecules
EP1141285A2 (en)	1998-12-16	2001-10-10	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1141284A2 (en)	1998-12-22	2001-10-10	Genentech, Inc.	Methods and compositions for inhibiting neoplastic cell growth
KR100887482B1 (ko)	1999-01-15	2009-03-10	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
EP1220905A2 (en)	1999-03-08	2002-07-10	Genentech Inc.	Composition and methods for the treatment of immune related diseases
EP2292761A1 (en)	1999-03-11	2011-03-09	Merck Serono S.A.	Vascular adhesion molecules and modulation of their function
US6642353B1 (en) *	1999-03-17	2003-11-04	Chugai Seiyaku Kabushiki Kaisha	Peptide ligands for the erythropoietin receptor
AU2883900A (en)	1999-07-07	2001-01-30	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666495A1 (en)	1999-12-01	2006-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6998468B2 (en) *	2000-03-23	2006-02-14	Tanox, Inc.	Anti-C2/C2a inhibitors of complement activation
CA2407715C (en) *	2000-04-29	2009-03-24	University Of Iowa Research Foundation	Diagnostics and therapeutics for macular degeneration-related disorders
CA2412211A1 (en)	2000-06-23	2002-01-03	Genetech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2896631A1 (en) *	2000-10-10	2015-07-22	Genentech, Inc.	Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
EP1326897A2 (en)	2000-10-13	2003-07-16	Biogen, Inc.	Humanized anti-lt-beta-r antibodies
CN101387646B (zh) *	2001-08-17	2016-08-10	建南德克公司	结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
AR040778A1 (es)	2002-08-06	2005-04-20	Glaxo Group Ltd	Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
AU2003258714A1 (en)	2002-09-06	2004-03-29	Cytos Biotechnology Ag	Immune modulatory compounds and methods
US7816497B2 (en) *	2002-10-30	2010-10-19	University Of Kentucky	Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) *	2003-04-09	2004-07-20	Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского"	Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (en) *	2003-07-03	2005-02-17	Euro-Celtique, S.A.	Genes associated with responses to neuropathic pain
US7923010B2 (en)	2003-09-11	2011-04-12	The Board Of Regents Of The University Of Texas System	Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) *	2004-02-03	2005-08-04	Leonard Bell	Method of treating hemolytic disease
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
BRPI0518289A2 (pt)	2004-11-18	2008-11-11	Univ Yale	mÉtodos e composiÇÕes para o tratamento de desordens oculares
WO2006071856A2 (en)	2004-12-23	2006-07-06	Glycofi, Inc.	Immunoglobulins comprising predominantly a man5glcnac2 glycoform
NZ608860A (en)	2005-02-14	2014-10-31	Univ Iowa Res Found	Methods and reagents for treatment and diagnosis of age-related macular degeneration
FI118793B (fi) *	2005-07-11	2008-03-31	Olli Friman	Rullaluistimen pyörän vierintälaakerin suojalevy
MX351152B (es)	2005-10-08	2017-10-04	Potentia Pharmaceuticals Inc	Compstatina y analogos de la misma para tratar trastornos oculares.
KR20180002911A (ko) *	2005-11-04	2018-01-08	제넨테크, 인크.	안질환 치료를 위한 보체 경로 억제제의 용도
US20070190057A1 (en)	2006-01-23	2007-08-16	Jian Wu	Methods for modulating mannose content of recombinant proteins
US7941135B2 (en)	2006-03-22	2011-05-10	Alcatel-Lucent Usa Inc.	Methods of performing live monitoring of a wireless communication network
CL2007003161A1 (es)	2006-11-02	2008-05-30	Genentech Inc	Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
AR066660A1 (es)	2007-05-23	2009-09-02	Genentech Inc	Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados

2007
- 2007-10-31 CL CL200703161A patent/CL2007003161A1/es unknown
- 2007-10-31 RS RS20181476A patent/RS58233B1/sr unknown
- 2007-10-31 KR KR1020167020466A patent/KR20160092061A/ko not_active Ceased
- 2007-10-31 JP JP2009535444A patent/JP2010508819A/ja not_active Withdrawn
- 2007-10-31 CN CN201610570102.6A patent/CN106084054A/zh active Pending
- 2007-10-31 PE PE2012000037A patent/PE20121034A1/es active IP Right Grant
- 2007-10-31 EP EP15151317.3A patent/EP2907827B1/en active Active
- 2007-10-31 MY MYPI20091788A patent/MY157948A/en unknown
- 2007-10-31 LT LTEP15151317.3T patent/LT2907827T/lt unknown
- 2007-10-31 US US11/931,060 patent/US8067002B2/en not_active Expired - Fee Related
- 2007-10-31 SI SI200732083T patent/SI2907827T1/sl unknown
- 2007-10-31 PE PE2007001490A patent/PE20081259A1/es active IP Right Grant
- 2007-10-31 CA CA2939806A patent/CA2939806A1/en not_active Abandoned
- 2007-10-31 EP EP07868632.6A patent/EP2097455B1/en active Active
- 2007-10-31 AU AU2007313685A patent/AU2007313685C1/en not_active Ceased
- 2007-10-31 KR KR1020097011297A patent/KR20090078364A/ko not_active Withdrawn
- 2007-10-31 RU RU2009120699A patent/RU2474589C9/ru not_active IP Right Cessation
- 2007-10-31 CN CN201610569910.0A patent/CN106188303A/zh active Pending
- 2007-10-31 PT PT78686326T patent/PT2097455E/pt unknown
- 2007-10-31 KR KR1020177026557A patent/KR20170110727A/ko not_active Ceased
- 2007-10-31 MY MYPI2013002530A patent/MY183804A/en unknown
- 2007-10-31 NZ NZ576812A patent/NZ576812A/en not_active IP Right Cessation
- 2007-10-31 KR KR1020147019915A patent/KR20140101873A/ko not_active Withdrawn
- 2007-10-31 KR KR1020157009721A patent/KR101645144B1/ko not_active Expired - Fee Related
- 2007-10-31 AR ARP070104846A patent/AR063760A1/es not_active Application Discontinuation
- 2007-10-31 ES ES15151317T patent/ES2700609T3/es active Active
- 2007-10-31 MX MX2009004665A patent/MX2009004665A/es active IP Right Grant
- 2007-10-31 CN CN201610570481.9A patent/CN106188304A/zh active Pending
- 2007-10-31 CN CN201510511513.3A patent/CN105085682A/zh active Pending
- 2007-10-31 UA UAA201214158A patent/UA116614C2/uk unknown
- 2007-10-31 NZ NZ596042A patent/NZ596042A/xx not_active IP Right Cessation
- 2007-10-31 NZ NZ609813A patent/NZ609813A/en not_active IP Right Cessation
- 2007-10-31 CN CN201610570520.5A patent/CN106188299A/zh active Pending
- 2007-10-31 SI SI200731587T patent/SI2097455T1/sl unknown
- 2007-10-31 TW TW103141058A patent/TW201534620A/zh unknown
- 2007-10-31 TW TW100142121A patent/TWI472535B/zh not_active IP Right Cessation
- 2007-10-31 PT PT15151317T patent/PT2907827T/pt unknown
- 2007-10-31 WO PCT/US2007/083172 patent/WO2008055206A2/en not_active Ceased
- 2007-10-31 PL PL15151317T patent/PL2907827T3/pl unknown
- 2007-10-31 CN CN200780048936.XA patent/CN101589063B/zh not_active Expired - Fee Related
- 2007-10-31 EP EP12152860A patent/EP2471818A1/en not_active Ceased
- 2007-10-31 DK DK07868632.6T patent/DK2097455T3/en active
- 2007-10-31 ES ES07868632.6T patent/ES2525477T3/es active Active
- 2007-10-31 DK DK15151317.3T patent/DK2907827T3/da active
- 2007-10-31 KR KR1020197000043A patent/KR20190003860A/ko not_active Ceased
- 2007-10-31 UA UAA200905597A patent/UA101603C2/ru unknown
- 2007-10-31 TW TW105127533A patent/TW201716437A/zh unknown
- 2007-10-31 TW TW096141085A patent/TWI391401B/zh not_active IP Right Cessation
- 2007-10-31 EP EP18190268.5A patent/EP3466971A1/en not_active Withdrawn
- 2007-10-31 TW TW107108695A patent/TW201843170A/zh unknown
- 2007-10-31 BR BRPI0716299-5A2A patent/BRPI0716299A2/pt active Search and Examination
- 2007-10-31 PL PL07868632T patent/PL2097455T3/pl unknown
- 2007-10-31 CA CA2667997A patent/CA2667997C/en not_active Expired - Fee Related
- 2007-10-31 CN CN201610570104.5A patent/CN106084055A/zh active Pending
2009
- 2009-05-03 IL IL198512A patent/IL198512A/en active IP Right Review Request
- 2009-05-05 ZA ZA2009/03088A patent/ZA200903088B/en unknown
- 2009-05-26 CR CR10827A patent/CR10827A/es unknown
- 2009-05-29 NO NO20092121A patent/NO20092121L/no not_active Application Discontinuation
- 2009-05-29 CO CO09055632A patent/CO6190543A2/es active IP Right Grant
- 2009-06-01 MA MA31941A patent/MA30962B1/fr unknown
- 2009-06-02 EC EC2009009379A patent/ECSP099379A/es unknown
2011
- 2011-01-14 US US13/007,142 patent/US8187604B2/en not_active Expired - Fee Related
- 2011-01-14 US US13/007,061 patent/US8193329B2/en not_active Expired - Fee Related
2012
- 2012-05-01 US US13/461,253 patent/US8372403B2/en not_active Expired - Fee Related
- 2012-10-25 JP JP2012235325A patent/JP2013027404A/ja active Pending
- 2012-10-25 JP JP2012235324A patent/JP5474158B2/ja not_active Expired - Fee Related
- 2012-11-06 RU RU2012147286A patent/RU2678802C2/ru not_active IP Right Cessation
2013
- 2013-02-05 US US13/759,613 patent/US8753826B2/en not_active Expired - Fee Related
- 2013-02-05 ZA ZA2013/00949A patent/ZA201300949B/en unknown
2014
- 2014-03-12 JP JP2014049395A patent/JP5918794B2/ja active Active
- 2014-05-20 US US14/282,063 patent/US20140303355A1/en not_active Abandoned
2015
- 2015-04-29 AR ARP150101290A patent/AR100225A2/es unknown
- 2015-04-29 IL IL238517A patent/IL238517B/en active IP Right Grant
- 2015-07-06 US US14/792,213 patent/US20160002352A1/en not_active Abandoned
- 2015-07-06 US US14/792,236 patent/US20160002353A1/en not_active Abandoned
- 2015-07-06 US US14/792,197 patent/US20150376295A1/en not_active Abandoned
- 2015-08-12 PH PH12015501763A patent/PH12015501763A1/en unknown
- 2015-09-01 JP JP2015171685A patent/JP2015214591A/ja not_active Withdrawn
2016
- 2016-03-29 HK HK16103589.3A patent/HK1215712A1/zh unknown
- 2016-07-29 US US15/224,366 patent/US20170166630A1/en not_active Abandoned
- 2016-12-23 HK HK16114632.7A patent/HK1226417A1/zh unknown
2017
- 2017-08-17 JP JP2017157499A patent/JP2017200492A/ja active Pending
- 2017-08-24 IL IL254137A patent/IL254137A0/en unknown
2018
- 2018-11-23 HR HRP20181969TT patent/HRP20181969T1/hr unknown
2019
- 2019-01-29 RU RU2019102393A patent/RU2019102393A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
TWI391401B (zh)	2013-04-01
CR10827A (es)	2009-09-07
KR101645144B1 (ko)	2016-08-03
CN106188304A (zh)	2016-12-07
US20160002352A1 (en)	2016-01-07
KR20190003860A (ko)	2019-01-09
CN101589063B (zh)	2016-08-31
PL2097455T3 (pl)	2015-04-30
US20170166630A1 (en)	2017-06-15
BRPI0716299A2 (pt)	2013-08-13
IL254137A0 (en)	2017-10-31
MX2009004665A (es)	2009-06-18
US8753826B2 (en)	2014-06-17
WO2008055206A2 (en)	2008-05-08
US8193329B2 (en)	2012-06-05
JP2013017490A (ja)	2013-01-31
RU2678802C2 (ru)	2019-02-01
AU2007313685A1 (en)	2008-05-08
KR20150046389A (ko)	2015-04-29
EP2097455A2 (en)	2009-09-09
EP2097455B1 (en)	2014-10-22
US20160002353A1 (en)	2016-01-07
SI2097455T1 (sl)	2015-03-31
TW201716437A (zh)	2017-05-16
US8372403B2 (en)	2013-02-12
EP2907827A1 (en)	2015-08-19
JP2014110810A (ja)	2014-06-19
JP2010508819A (ja)	2010-03-25
PL2907827T3 (pl)	2019-03-29
UA116614C2 (uk)	2018-04-25
AU2007313685A8 (en)	2009-06-18
KR20170110727A (ko)	2017-10-11
PH12015501763A1 (en)	2019-04-29
PE20121034A1 (es)	2012-08-25
JP2017200492A (ja)	2017-11-09
AU2007313685C1 (en)	2015-09-17
TW201843170A (zh)	2018-12-16
CN106084054A (zh)	2016-11-09
JP5918794B2 (ja)	2016-05-18
ECSP099379A (es)	2009-07-31
PT2907827T (pt)	2018-12-04
JP5474158B2 (ja)	2014-04-16
TW200827373A (en)	2008-07-01
HK1138018A1 (zh)	2010-08-13
DK2907827T3 (da)	2019-01-02
TWI472535B (zh)	2015-02-11
CN105085682A (zh)	2015-11-25
TW201534620A (zh)	2015-09-16
US20130171070A1 (en)	2013-07-04
WO2008055206A3 (en)	2008-09-04
RU2474589C2 (ru)	2013-02-10
US20140303355A1 (en)	2014-10-09
HK1215712A1 (zh)	2016-09-09
EP3466971A1 (en)	2019-04-10
IL238517A0 (en)	2015-06-30
EP2471818A1 (en)	2012-07-04
NO20092121L (no)	2009-07-24
TW201211063A (en)	2012-03-16
HRP20181969T1 (hr)	2019-02-08
IL198512A (en)	2015-05-31
CO6190543A2 (es)	2010-08-19
JP2015214591A (ja)	2015-12-03
ES2525477T3 (es)	2014-12-23
RU2019102393A (ru)	2020-07-29
RU2474589C9 (ru)	2019-08-15
US20080118506A1 (en)	2008-05-22
US8067002B2 (en)	2011-11-29
AR063760A1 (es)	2009-02-18
US20110123528A1 (en)	2011-05-26
US8187604B2 (en)	2012-05-29
HK1226417A1 (zh)	2017-09-29
CN101589063A (zh)	2009-11-25
CA2667997A1 (en)	2008-05-08
MY157948A (en)	2016-08-30
CN106188299A (zh)	2016-12-07
IL198512A0 (en)	2011-08-01
US20110165622A1 (en)	2011-07-07
MA30962B1 (fr)	2009-12-01
EP2907827B1 (en)	2018-09-19
ES2700609T3 (es)	2019-02-18
SI2907827T1 (sl)	2019-02-28
KR20160092061A (ko)	2016-08-03
RU2009120699A (ru)	2010-12-10
DK2097455T3 (en)	2014-12-15
KR20140101873A (ko)	2014-08-20
MY183804A (en)	2021-03-16
US20120230985A1 (en)	2012-09-13
WO2008055206A9 (en)	2008-07-17
LT2907827T (lt)	2018-12-10
CA2667997C (en)	2016-10-11
RS58233B1 (sr)	2019-03-29
RU2012147286A (ru)	2014-05-20
UA101603C2 (ru)	2013-04-25
PT2097455E (pt)	2015-02-05
AR100225A2 (es)	2016-09-21
NZ596042A (en)	2013-06-28
NZ609813A (en)	2015-01-30
HK1213920A1 (en)	2016-07-15
CN106188303A (zh)	2016-12-07
AU2007313685B2 (en)	2013-01-24
US20150376295A1 (en)	2015-12-31
ZA201300949B (en)	2016-05-25
JP2013027404A (ja)	2013-02-07
PE20081259A1 (es)	2008-10-31
ZA200903088B (en)	2013-05-29
NZ576812A (en)	2011-11-25
CN106084055A (zh)	2016-11-09
IL238517B (en)	2018-05-31
KR20090078364A (ko)	2009-07-17
CA2939806A1 (en)	2008-05-08

Publication	Publication Date	Title
CL2007003161A1 (es)	2008-05-30	Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
CL2013001824A1 (es)	2014-03-28	Composicion adecuada para el control de enfermedades en las plantas causadas por fitopatogenos, metodo para controlar enfermedades en plantas utiles o en su material de propagacion causadas por fitopatogenos, y metodo para controlar enfermedades en plantas de soja causadas por fitopatogenos
AR078516A1 (es)	2011-11-16	Moleculas de union a dll-4 (ligando 4 de tipo delta)
BRPI0820238A2 (pt)	2015-06-16	Processo de produção de ácido tereftálico e respectivas composições
FI20075794L (fi)	2009-05-10	Integroitu prosessi diesel-polttoaineen valmistamiseksi biologisesta materiaalista ja prosessiin liittyvät tuotteet, käyttötavat ja laitteisto
CL2007002987A1 (es)	2008-06-06	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3.
BR112012015740A2 (pt)	2017-04-25	anticorpos de anti-flt3 e metodos de uso dos mesmos
AR081452A1 (es)	2012-09-05	APTAMEROS PARA b-NGF Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS MEDIADOS POR b-NGF
BRPI0814815A2 (pt)	2015-02-03	Processo para tratar uma formação subterrânea
CL2007002989A1 (es)	2008-05-16	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para el diagnostico de enfermedades relacionadas con notch3.
MX2017009153A (es)	2018-02-01	Proteinas de fusion de citoquinas.
CL2008001334A1 (es)	2008-09-22	Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
MX276615B (es)	2010-06-15	Proceso para preparar prepolimeros de poliuretano actinicamente curables que contienen alofanato con resistencia incrementada.
AR081515A1 (es)	2012-10-03	Agente de sustentacion de un material vitroceramico
BR112013007862A2 (pt)	2019-09-24	ácidos nucleicos manipulados e métodos de uso dos mesmos.
CL2011002611A1 (es)	2012-07-20	Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
PT2617823E (pt)	2015-11-23	Fitases, ácidos nucleicos que as codificam e métodos para as preparar e utilizar
ECSP12011835A (es)	2012-06-29	Moléculas de unión biespecíficas para la terapia anti-angiogénesis.
ES2531167T5 (es)	2018-05-21	Amilasas y glucoamilasas, ácidos nucleicos que las codifican y métodos para formarlas y utilizarlas
BRPI0717068A2 (pt)	2013-09-24	instruÇço e làgica para processar cadeias de texto.
CL2013002044A1 (es)	2014-05-09	Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
CL2007002767A1 (es)	2008-05-30	Anticuerpo especifico para el receptor ccr5; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar enfermedades inmunosupresoras.
BRPI0716943A2 (pt)	2013-09-17	processo para produzir uma alimentaÇço de enriquecimento
CL2008000478A1 (es)	2008-10-17	Elemento de union aislado especifico para inmunoglobulina e (ige); molecula de acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y su uso para tratar trastornos asociados con ige.
CL2007003357A1 (es)	2008-04-04	Anticuerpo o fragmento funcional del mismo capaz de inhibir la proliferacion de celulas tumorales in vitro y/o in vivo; acido nucleico que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar el cancer.